DX32
Beltrims: Belgian Treatment Registry in MS
Untill 2012, there was no registry in Belgium dedicated to MS patients. In order to establish a registry that would capture MS patients treated with new disease modifying treatments, the Belgian Study Group for Multiple Sclerosis (BSGMS) established a working party to create a Belgian MS registry.
Objectives:
Independent of the pharmaceutical industry, we want to collect data on patient profiles, short- and longterm adverse events (known and unknown, with special interest for infections and malignancies), possible interactions between medications, motivations and results of switching from one to another immunomodulatory or immunosuppressive drug, real-life efficacy data (annualized relapse rate, EDSS, MRI data), and pregnancy outcomes.
Methods:
The BELTRIMS registry is an ongoing longitudinal observational registry that captures outcomes of MS patients treated with new DMTs. Once a patient has been registered, follow up will be ongoing, even if the new treatment is stopped. No experimental interventions are involved. Treatments and assessments are determined by the treating neurologist and dictated by clinical practice and available guidelines. A steering committee decides on the data analysis. Participating neurologists are all members of the BSGMS and have expertise in treating MS patients and have EDSS-neurostatus certification. Participation is on a voluntary basis.
Results:
As of May 2017, 1041 patients were registered. 72 neurologists from 34 centers are involved of which 25 are actively encoding patients. 12 centers have included more than 10 patients each. Baseline demographic data and current treatments will be presented.
Conclusions:
The BELTRIMS registry is a recently established registry that is fueled by MS neurologists who are members of the BSGMS. It reflects the current treatment practice in Belgium and data is continuously added.